Patents Examined by Gabrielle Bugaisky
  • Patent number: 6573364
    Abstract: The present invention relates to complexes of the HPS protein with proteins identified as interacting with HPS protein by a modified yeast two hybrid assay system. The proteins identified to interact with HPS protein are 14-3-3 protein, Hrs, atrophin-1, DGS-I, nuclear factor NF90, HPIP1 and human HN1 homolog protein. Accordingly, the present invention discloses complexes of HPS protein and 14-3-3 protein, Hrs, atrophin-1, DGS-I, nuclear factor NF90, HPIP1 and human HN1 homolog protein, and derivatives, fragments and analogs thereof. Additionally, the present invention also discloses nucleic acids encoding the HPIP1 and human HN1 homolog protein, or derivatives, fragments and analogs thereof. Methods of screening the complexes or proteins for efficacy in treating and/or preventing certain diseases and disorders, particularly atopic diseases, autoimmune diseases, neurodegenerative disease, cancer, pigmentation disorders, platelet dysfunction and viral diseases, are also disclosed herein.
    Type: Grant
    Filed: March 10, 1999
    Date of Patent: June 3, 2003
    Assignee: Curagen Corporation
    Inventors: Krishnan Nandabalan, Meijia Yang
  • Patent number: 6573240
    Abstract: Novel Bacillus thuringiensis genes encoding toxins which are active against lepidopteran insects have been cloned from novel lepidopteran-active B. thuringiensis microbes. The DNA encoding the B. thuringiensis toxins can be used to transform various prokaryotic and eukaryotic microbes to express the B. thuringiensis toxins. These recombinant microbes can be used to control lepidopteran insects in various environments.
    Type: Grant
    Filed: March 9, 2000
    Date of Patent: June 3, 2003
    Assignee: Mycogen Corporation
    Inventors: Jewel Payne, August J. Sick
  • Patent number: 6555655
    Abstract: Disclosed are novel insecticidal polypeptides, and compositions comprising these polypeptides, peptide fragments thereof, and antibodies specific therefor. Also disclosed are vectors, transformed host cells, and transgenic plants that contain nucleic acid segments that encode the disclosed &dgr;-endotoxin polypeptides. Also disclosed are methods of identifying related polypeptides and polynucleotides, methods of making and using transgenic cells comprising these polynucleotide sequences, as well as methods for controlling an insect population, such as Colorado potato beetle, southern corn rootworm and western corn rootworm, and for conferring to a plant resistance to a target insect species.
    Type: Grant
    Filed: May 3, 2000
    Date of Patent: April 29, 2003
    Assignee: Monsanto Technology, LLC
    Inventors: Mark J. Rupar, William P. Donovan, Chih-Rei Chu, Elizabeth Pease, Yuping Tan, Annette C. Slaney, Thomas M. Malvar, James A. Baum
  • Patent number: 6555116
    Abstract: Thioredoxin, a small dithiol protein, is a specific reductant for allergenic proteins and particularly allergenic proteins present in pollen and animal and plant sources. All targeted proteins contain disulfide (S—S) bonds that are reduced to the sulfhydryl (SH) level by thioredoxin. The proteins are allergenically active and less digestible in the oxidized (S—S) state. When reduced (SH state), they lose their allergenicity and/or become more digestible. Thioredoxin achieved this reduction when activated (reduced) either by NADPH via NADP-thioredoxin reductase (physiological conditions) or by lipoic acid chemical reductant. Skin tests carried out with sensitized dogs showed that treatment of the pollens with reduced thioredoxin prior to injection eliminated or decreased the allergenicity of the pollen. Studies showed increased digestion of the pollen proteins by pepsin following reduction by thioredoxin.
    Type: Grant
    Filed: January 27, 1999
    Date of Patent: April 29, 2003
    Assignee: Regents of the University of California
    Inventors: Bob B. Buchanan, Gregorio del Val, Rosa M. Lozano, Joshua H. Wong, Boihon C. Yee, Oscar L. Frick
  • Patent number: 6548276
    Abstract: Compositions and methods are provided for the enhanced in vitro synthesis of polypeptides containing disulfide bonds. In order to improve the performance of in vitro protein synthesis reactions, pre-treatment and redox buffering of the reaction mix is performed in order to optimize the redox potential. Exogenous enzymes that enhance protein folding and disulfide bond formation may also be added to the reaction.
    Type: Grant
    Filed: September 5, 2001
    Date of Patent: April 15, 2003
    Assignee: The Board of Trustees of the Leland Stanford Junior University
    Inventors: James Robert Swartz, Dong-Myung Kim
  • Patent number: 6548060
    Abstract: Aminoacyl-tRNA synthetases are the enzymes catalyzing ligation of their cognate amino acids and tRNAs. Human glutaminyl-tRNA synthetase (QRS) consists of the unique N-terminal extension (236 aa) and the C-terminal catalytic domain (539 aa). Here, we found that the N- and C-domains of QRS interacted with pro-apoptotic mediator, Daxx, and its downstream kinase, ASK1 (apoptosis signal-regulating kinase), respectively. The experimental results suggest that QRS may inhibit the ASK1 activity via two different ways. First, its C-terminal domain made direct inhibitory interaction with ASK1. Second, it inhibited the pro-apoptotic interaction between Daxx and ASK1. QRS also blocked the Daxx-ASK1 mediated apoptosis.
    Type: Grant
    Filed: November 18, 1999
    Date of Patent: April 15, 2003
    Inventor: Sunghoon Kim
  • Patent number: 6545126
    Abstract: A chimeric toxin is disclosed. In a preferred embodiment, the chimeric toxin comprises a botulinal neurotoxin heavy chain and non-clostridial toxin chain. A method of creating a chimeric toxin is also disclosed. The chimeric toxin will have utility for pharmacological treatment of neurological disorders.
    Type: Grant
    Filed: March 14, 2000
    Date of Patent: April 8, 2003
    Assignee: Wisconsin Alumni Research Foundation
    Inventors: Eric A. Johnson, Michael C. Goodnough, Carl J. Malizio, Alan B. Scott
  • Patent number: 6531298
    Abstract: A non-naturally occuring Factor IX protein having an amino acid substitution at amino acid position 338 is provided. Preferred substitutions include the substitution of analanine, leucine, or valine for the arginine at amino acid position 338. Factor IX of the present invention is non-naturally occuring (e.g., does not contain only an arginine to proline substitution at amino acid position 338). Factor IX proteins of the invention are useful for facilitating blood clotting in subjects in need thereof, such as subjects afflicted with hemophilia B. Pharmaceutical formulations comprising Factor IX of the invention are provided, along with nucleic acids encoding the factor and vectors containing such nucleic acids.
    Type: Grant
    Filed: July 17, 1998
    Date of Patent: March 11, 2003
    Assignee: The University of North Carolina at Chapel Hill
    Inventors: Darrel W. Stafford, Jin Li Chang
  • Patent number: 6528484
    Abstract: Proteins from the genus Photorhabdus are toxic to insects upon exposure. Photorhabdus luminescens (formerly Xenorhabdus luminescens) have been found in mammalian clinical samples and as a bacterial symbiont of entomopathogenic nematodes of genus Heterorhabditis. These protein toxins can be applied to, or genetically engineered into, insect larvae food and plants for insect control.
    Type: Grant
    Filed: May 5, 1997
    Date of Patent: March 4, 2003
    Assignee: Wisconsin Alumni Research Foundation
    Inventors: Jerald C. Ensign, David J. Bowen, James Petell, Raymond Fatig, Sue Schoonover, Richard H. ffrench-Constant, Thomas A. Rocheleau, Michael B. Blackburn, Timothy D. Hey, Donald J. Merlo, Gregory L. Orr, Jean L. Roberts, James A. Strickland, Lining Guo, Todd A. Ciche, Kitisri Sukhapinda
  • Patent number: 6524579
    Abstract: The invention provides human RNA binding proteins (RNABP) and polynucleotides which identify and encode RNABP. The invention also provides expression vectors, host cells, antibodies, agonists, and antagonists. The invention also provides methods for diagnosing, treating or preventing disorders associated with expression of RNABP.
    Type: Grant
    Filed: October 20, 1999
    Date of Patent: February 25, 2003
    Assignee: Incyte Genomics, Inc.
    Inventors: Olga Bandman, Neil C. Corley, Karl J. Guegler, Mariah R. Baughn
  • Patent number: 6524580
    Abstract: A method for treating hypothyroidism by local administration of a neurotoxin, such as a botulinum toxin, to a thyroid, thereby reducing an inhibitory effect upon thyroid hormone secretion. A method for treating hyperthyroidism by local administration of a neurotoxin, such as a botulinum toxin, to a sympathetic ganglion which innervates the thyroid, thereby reducing a stimulatory effect upon thyroid hormone secretion. Methods for treating calcium metabolism disorders by local administration of a neurotoxin to modulate calcitonin secretion are also disclosed.
    Type: Grant
    Filed: February 15, 2000
    Date of Patent: February 25, 2003
    Assignee: Allergan Sales, Inc.
    Inventor: Stephen Donovan
  • Patent number: 6509039
    Abstract: The invention relates to cross linked products of chitosan or gelatin and of a carboxylic acid di- or polyanhydride. These products form hydrogels with a wide variety of applications, preferably in the medical/pharmaceutical sector.
    Type: Grant
    Filed: July 21, 2000
    Date of Patent: January 21, 2003
    Assignee: Merck Patent Gesellschaft
    Inventor: Berthold Nies
  • Patent number: 6506726
    Abstract: A method is described for separating and purifying a wide variety of fermentation cyclopeptide products containing at least one protonatable amino group (including the deacylated Echinocandin-type compounds) from their fermentation or mixed broths and partially purified process streams by adsorbing the mixture onto a hydrophobic, reversed phase chromatographic media and eluting with a continuous linear acetic acid gradient ranging from 0.1% acetic acid to 10.0% acetic acid by volume in water. A process for removing tripeptide-aldehyde by-products from the fermentation products by means of a derivatizing agent is also described.
    Type: Grant
    Filed: December 10, 2001
    Date of Patent: January 14, 2003
    Assignee: Eli Lilly and Company
    Inventors: John Robert Dobbins, Eugene Paul Kroeff, Jeffrey Thomas Vicenzi
  • Patent number: 6503500
    Abstract: The invention provides a biocontrol agent against larvae of mosquitoes and blackflies comprising transgenic Anabaena PCC 7120 carrying a synergistic combination of the endotoxin genes CryIVA and CryIVD of Bacillus thuringiensis subsp. israelensis.
    Type: Grant
    Filed: November 13, 1998
    Date of Patent: January 7, 2003
    Assignee: Ben Gurion University of the Negev Research and Development Authority
    Inventors: Arieh Zaritsky, Sammy Boussiba, Eitan Ben-Dov
  • Patent number: 6504022
    Abstract: The invention provides an isolated gene and an isolated nucleic acid sequence encoding human Bad and functional fragments thereof. Also provided is an isolated human Bad polypeptide and functional fragments thereof. Methods of identifying human Bad binding partners and methods of screening for compounds which interfere with the association of human Bad interacting polypeptides with human Bad are also provided. Finally, methods for decreasing or increasing the viability of a cell are provided as well.
    Type: Grant
    Filed: August 16, 1999
    Date of Patent: January 7, 2003
    Assignee: IDUN Pharmaceuticals, Inc.
    Inventors: William A. Horne, Tilman Oltersdorf
  • Patent number: 6472205
    Abstract: The present invention is directed to nucleic acid molecules that encode a cytosolic form of beta-lactamase, cells that include such nucleic acid molecules and methods for their use. These cells can be used in a variety of methods, such as methods for monitoring the expression of a gene or biochemical activity.
    Type: Grant
    Filed: January 11, 2000
    Date of Patent: October 29, 2002
    Assignee: The Regents of the University of California
    Inventors: Roger Y. Tsien, Gregor Zlokarnik
  • Patent number: 6472170
    Abstract: The present invention relates to BCL-x&ggr;, a novel isoform of the BCL-x family of proteins which is predominantly expressed in T-lymphocytes and is associated with resistance to apoptosis. Both compositions of matter and methods are described which are useful in the treatment or prevention of immune system disorders.
    Type: Grant
    Filed: July 23, 1997
    Date of Patent: October 29, 2002
    Assignee: Dana-Farber Cancer Institute
    Inventors: Xiao-Feng Yang, Georg F. Weber, Harvey Cantor
  • Patent number: 6472189
    Abstract: An isolated esterase gene coding for an esterase capable of causing asymmetric hydrolysis of an organic carboxylic acid ester of a cyclopentenolone of formula I: wherein R1 is hydrogen or methyl, and R2 is C1-C10 alkyl, C2-C10 alkenyl, C2-C10 alkynyl, C1-C4 haloalkyl, a C5-C9 aliphatic hydrocarbon moiety which may be optionally protected on the terminal hydroxyl group thereof, or a C5-C9 fatty acid residue which may be optionally protected on the terminal carboxyl group thereof, to produce the cyclopentenolone of formula I in (R)-form, and hybridizing to the base sequence of SEQ ID NO:1, is useful for the industrially favorable production of optically active cyclopentenolones of formula I which serve as the intermediates of drugs, agricultural chemicals or other active products.
    Type: Grant
    Filed: December 23, 1998
    Date of Patent: October 29, 2002
    Assignee: Sumitomo Chemical Company, Limited
    Inventors: Takeshi Ishii, Satoshi Mitsuda
  • Patent number: 6468523
    Abstract: Disclosed is a novel Lepidopteran- and Coleopteran-active &dgr;-endotoxin polypeptide, and compositions comprising the polypeptide, peptide fragments thereof, and antibodies specific therefor. Also disclosed are vectors, transformed host cells, and transgenic plants that comprise nucleic acid segments encoding the polypeptide. Also disclosed are methods of identifying related polypeptides and polynucleotides, methods of making and using transgenic cells comprising the novel sequences of the invention, as well as methods for controlling an insect population, such as the Western Corn Rootworm and Colorado potato beetle, and for conferring to a plant population resistance to the target insect species.
    Type: Grant
    Filed: November 2, 1998
    Date of Patent: October 22, 2002
    Assignee: Monsanto Technology LLC
    Inventors: Anne-Marie Light Mettus, James A. Baum
  • Patent number: 6462176
    Abstract: Novel polypeptides, designated Apo-3, which are capable of stimulating or inducing apoptosis are provided. Compositions including Apo-3 chimeras, nucleic acid encoding Apo-3, and antibodies to Apo-3 are also provided.
    Type: Grant
    Filed: September 11, 1997
    Date of Patent: October 8, 2002
    Assignee: Genentech, Inc.
    Inventor: Avi J. Ashkenazi